{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-093921","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2023-08-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.790697+00:00","generated_at":"2026-06-11T06:04:32.263543+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sagimet Q2 net loss $6.8M; IPO raised $86.2M net; denifanstat 67% fat reduction","bullets":["IPO closed July 18: 6,026,772 shares at $16; gross proceeds $96.4M, net $86.2M.","Cash $18.5M at June 30; combined with IPO proceeds extends runway into Q1 2025.","Phase 2b FASCINATE-2 interim: 67% denifanstat achieved ≥30% liver fat reduction vs 18% placebo (p<0.001).","Tony Rimac appointed CFO (previously COO) after Dennis Hom departure; Liz Rozek as General Counsel & CCO.","Net loss $13.4M for H1 2023; R&D $9.2M, G&A $4.7M; no FY2023 guidance provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-093921","json":"https://secwatch.observer/filing/0001104659-23-093921.json","markdown":"https://secwatch.observer/filing/0001104659-23-093921.md","text":"https://secwatch.observer/filing/0001104659-23-093921.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465923093921/0001104659-23-093921-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465923093921/tm2323988d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T06:04:32.263543+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34a37deed91fbed0f48a6bad37c8564dc6145467","claim":"Sagimet Biosciences Inc. reported the second quarter ended June 30, 2023 results: net income Net loss for the second quarter ended June 30, 2023 was $6.8 million.","evidence_excerpt":"Net loss for the second quarter ended June 30, 2023 was $6.8 million compared to a net loss of $7.1 million for the second quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465923093921/0001104659-23-093921-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss for the second quarter ended June 30, 2023 was $6.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"8ddc7a8f49aa5c40934a1ec2fdd80e8bf70d311c","claim":"Sagimet Biosciences Inc. reported the six months ended June 30, 2023 results: net income The net loss for the six months ended June 30, 2023 totaled $13.4 million.","evidence_excerpt":"The net loss for the six months ended June 30, 2023 totaled $13.4 million compared to $15.8 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1400118/000110465923093921/0001104659-23-093921-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended June 30, 2023"},{"label":"Net income","value":"The net loss for the six months ended June 30, 2023 totaled $13.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}